A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets. Through our leading portfolio of comprehensive molecular diagnostic tests, we are focused on progressing patient care from the current standard to a more individualized approach, leveraging each patient’s unique cancer biology to improve their outcomes. We serve global markets with two complementary models.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 517M | 517M | 446M | 361M | 297M | 220M |
| Net Income | 66M | 66M | 24M | -74M | -37M | -76M |
| EPS | $0.82 | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
| Free Cash Flow | 127M | 127M | 64M | 34M | -1.0M | -37M |
| ROIC | 5.7% | 6.9% | 2.3% | -7.0% | -3.4% | -10.0% |
| Gross Margin | 70.1% | 70.1% | 66.9% | 63.6% | 59.2% | 31.4% |
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.01 | 0.01 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 58M | 58M | 16M | -86M | -41M | -82M |
| Operating Margin | 11.2% | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% |
| ROE | 5.1% | 5.3% | 2.2% | -7.0% | -3.4% | -10.0% |
| Shares Outstanding | 81M | 81M | 78M | 73M | 72M | 68M |
VERACYTE, INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
VERACYTE, INC. trades at 39.6x trailing earnings, compared to its 15-year median P/E of 51.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 20.4x vs a median of 49.0x. The company's 5-year average gross margin is 58.2%. At current prices, the estimated annualized return to fair value is +90.9%.
VERACYTE, INC. (VCYT) has a current P/E ratio of 39.6, compared to its historical median P/E of 51.8. The stock is currently considered Cheap based on its historical valuation range.
VERACYTE, INC. (VCYT) has a 5-year average return on invested capital (ROIC) of -2.2%. This is below average and may indicate limited pricing power.
VERACYTE, INC. (VCYT) has a market capitalization of $2.6B. It is classified as a mid-cap stock.
VERACYTE, INC. (VCYT) does not currently pay a regular dividend.
Based on historical P/E analysis, VERACYTE, INC. (VCYT) appears cheap. The current P/E of 39.6 is 24% below its historical median of 51.8.
VERACYTE, INC. (VCYT) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
VERACYTE, INC. (VCYT) reported annual revenue of $517 million in its most recent fiscal year, based on SEC EDGAR filings.
VERACYTE, INC. (VCYT) has a net profit margin of 12.8%. This is a healthy margin.
VERACYTE, INC. (VCYT) generated $127 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
VERACYTE, INC. (VCYT) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
VERACYTE, INC. (VCYT) reported earnings per share (EPS) of $0.82 in its most recent fiscal year.
VERACYTE, INC. (VCYT) has a return on equity (ROE) of 5.3%. This indicates moderate shareholder returns.
VERACYTE, INC. (VCYT) has a 5-year average gross margin of 58.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for VERACYTE, INC. (VCYT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VERACYTE, INC. (VCYT) has a book value per share of $16.18, based on its most recent annual SEC filing.